CA2128331A1 - Methodes d'utilisation de derives histaminiques comme immunomodulateurs ou produits immunotherapeutiques - Google Patents

Methodes d'utilisation de derives histaminiques comme immunomodulateurs ou produits immunotherapeutiques

Info

Publication number
CA2128331A1
CA2128331A1 CA002128331A CA2128331A CA2128331A1 CA 2128331 A1 CA2128331 A1 CA 2128331A1 CA 002128331 A CA002128331 A CA 002128331A CA 2128331 A CA2128331 A CA 2128331A CA 2128331 A1 CA2128331 A1 CA 2128331A1
Authority
CA
Canada
Prior art keywords
histamine
chain
substituted
protein allergen
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002128331A
Other languages
English (en)
Inventor
Julia L. Greenstein
Kenneth L. Melmon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immulogic Pharmaceutical Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2128331A1 publication Critical patent/CA2128331A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from plants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002128331A 1992-01-21 1993-01-19 Methodes d'utilisation de derives histaminiques comme immunomodulateurs ou produits immunotherapeutiques Abandoned CA2128331A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82322992A 1992-01-21 1992-01-21
US07/823,229 1992-01-21

Publications (1)

Publication Number Publication Date
CA2128331A1 true CA2128331A1 (fr) 1993-07-22

Family

ID=25238155

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002128331A Abandoned CA2128331A1 (fr) 1992-01-21 1993-01-19 Methodes d'utilisation de derives histaminiques comme immunomodulateurs ou produits immunotherapeutiques

Country Status (7)

Country Link
EP (1) EP0621780A1 (fr)
JP (1) JPH07503239A (fr)
CN (1) CN1078153A (fr)
AU (1) AU3591793A (fr)
CA (1) CA2128331A1 (fr)
MX (1) MX9300294A (fr)
WO (1) WO1993013772A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004075845A2 (fr) * 2003-02-24 2004-09-10 The Board Of Trustees Of The Leland Stanford Junior University Methodes de traitement ou de prevention d'une maladie auto-immune par l'utilisation d'agents bloquants du recepteur h1 de l'histamine
PL1928492T3 (pl) * 2005-09-01 2011-09-30 Celgene Corp Immunologiczne zastosowania związków immunomodulujących do szczepionki i przeciwzakaźnego leczenia choroby
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
US10935554B2 (en) 2013-08-23 2021-03-02 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT)
RS67826B1 (sr) 2016-12-22 2026-03-31 Regeneron Pharma Postupak za lečenje alergije sa monoklonskim antitelima specifičnim za alergen
JP7112409B2 (ja) * 2017-01-24 2022-08-03 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 抗Ｆｅｌ Ｄ１抗体を含む組成物及びヒトのネコアレルギーの少なくとも１つの症状を減少させる方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996221A (en) * 1987-01-13 1991-02-26 The Board Of Trustees Of The Leland Stanford Junior University Histamine derivatives as immune modulators

Also Published As

Publication number Publication date
AU3591793A (en) 1993-08-03
JPH07503239A (ja) 1995-04-06
WO1993013772A1 (fr) 1993-07-22
CN1078153A (zh) 1993-11-10
MX9300294A (es) 1994-01-31
EP0621780A1 (fr) 1994-11-02

Similar Documents

Publication Publication Date Title
RU2236257C1 (ru) Синтетический иммуноген для терапии и профилактики злоупотреблений наркотическими и психоактивными веществами
ES2205231T3 (es) Procedimiento de tratamiento de la hipersensibilidad de tipo i que utilizan monofosforil lipido a.
CN1127983C (zh) 免疫调节、抗炎症剂
JPH02501066A (ja) ＩｇＥ非関与型疾病の治療方法および治療用ペプチド
Bartfeld et al. Specific immunosuppression of experimental autoimmune myasthenia gravis by denatured acetylcholine receptor.
US6699973B1 (en) Antibodies to peptides that target GIT receptors and related methods
WO1993014755A1 (fr) Derives d'histamine et procedes d'utilisation comme immunomodulateurs
CA2128331A1 (fr) Methodes d'utilisation de derives histaminiques comme immunomodulateurs ou produits immunotherapeutiques
Ahlstedt et al. Specific antibody responses in rats and mice after daily immunization without adjuvant
Cara et al. Immunological induction of flavour aversion in mice. II. Passive/adoptive transfer and pharmacological inhibition
US4891219A (en) Method for immunization against and treatment of infection by ectoparasites and endoparasites
Fujimaki et al. Adjuvant effects of aluminum silicate on IgE and IgG1 antibody production in mice
US4702907A (en) Process for inducing selective immunosuppression of antibodies
Galle et al. Vaccination with IL-6 analogues induces autoantibodies to IL-6 and influences experimentally induced inflammation
HayGlass et al. Isotype‐selective abrogation of established IgE responses
US6271202B1 (en) Reduction of impairment of respiratory tract mucosal immunity
Weinbaum et al. Comparison of cross-reactivities between albumins of various species at the level of antibody and helper T cells—studies in mice
Kemeny et al. Immune response to bee venom: II. Quantitation of the absolute amounts of IgE and IgG antibodies by saturation analysis
Mitchell et al. Lung granulomatous hypersensitivity to eggs of Schistosoma japonicum in mice analysed by a radioisotopic assay and effects of hybridoma (idiotype) sensitization
JP2002249442A (ja) アレルギー減感作治療薬
RU2182492C1 (ru) Лекарственное средство для лечения наркотической зависимости
WO1993014754A1 (fr) Derives d'histamine et leurs procedes d'utilisation comme immunomodulateurs
Gamaleya et al. Induction of antibodies to morphine during chronic morphine treatment in rodents and opiate addicts
JP7678465B1 (ja) 抗ＩｇＥ抗体誘導用ワクチン組成物
Wheeler et al. Adjuvant properties of hydrophobic derivatives prepared from L-tyrosine

Legal Events

Date Code Title Description
FZDE Dead